149 related articles for article (PubMed ID: 21478328)
21. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
[TBL] [Abstract][Full Text] [Related]
22. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
Paoletti E; Amidone M; Cassottana P; Gherzi M; Marsano L; Cannella G
Am J Kidney Dis; 2008 Aug; 52(2):324-30. PubMed ID: 18585837
[TBL] [Abstract][Full Text] [Related]
23. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
24. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
Chen YH; Li C; Lan KK
Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
[TBL] [Abstract][Full Text] [Related]
25. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
26. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
[TBL] [Abstract][Full Text] [Related]
27. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
28. The role of fibroblast growth factor-23 in left atrial volume.
Ratanapo S; Kittanamongkolchai W; Srivali N; Ahmed S; Cheungpasitporn W; Chongnarungsin D
Am Heart J; 2013 May; 165(5):e21. PubMed ID: 23622923
[No Abstract] [Full Text] [Related]
29. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
Wu PS; Lin M; Chow SC
J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
[TBL] [Abstract][Full Text] [Related]
30. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
Meems LM; Cannon MV; Mahmud H; Voors AA; van Gilst WH; Silljé HH; Ruifrok WP; de Boer RA
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):282-9. PubMed ID: 22800987
[TBL] [Abstract][Full Text] [Related]
31. Heart remodeling and ischemia-reperfusion arrhythmias linked to myocardial vitamin d receptors deficiency in obstructive nephropathy are reversed by paricalcitol.
Diez ER; Altamirano LB; García IM; Mazzei L; Prado NJ; Fornes MW; Carrión FD; Zumino AZ; Ferder L; Manucha W
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):211-20. PubMed ID: 24924917
[TBL] [Abstract][Full Text] [Related]
32. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
35. [Left ventricular hypertrophy in paediatric predialysis children and treatment--induced regression of left ventricular mass].
Borzych D; Zurowska A; Bałasz I; Sabiniewicz R; Ereciński J
Wiad Lek; 2005; 58 Suppl 1():55-7. PubMed ID: 16060086
[TBL] [Abstract][Full Text] [Related]
36. Patterns of left ventricular hypertrophy in chronic kidney disease: an echocardiographic evaluation.
Sambi RS; Gaur AK; Hotchandani R; Aggarwal KK; Kaur S; Gupta M; Jain S; Krishna CK; Chopra HK; Anand V; Srivastava S; Gupta R; Parashar SK
Indian Heart J; 2011; 63(3):259-68. PubMed ID: 22734347
[TBL] [Abstract][Full Text] [Related]
37. Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial.
Higuchi T; Abe M; Yamazaki T; Okawa E; Ando H; Hotta S; Oikawa O; Kikuchi F; Okada K; Soma M
Am J Kidney Dis; 2016 Feb; 67(2):260-70. PubMed ID: 26508680
[TBL] [Abstract][Full Text] [Related]
38. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
39. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
40. Sample size adjustment designs with time-to-event outcomes: A caution.
Freidlin B; Korn EL
Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
